 The ten schizophrenic subjects in Aim 1 will be switched from standard antipsychotic treatment to twelve weeks of open label aripiprazole and retested with the fMRI monetary reward task. We predict that twelve weeks of aripiprazole treatment will normalize the activation of OFC and ACC in response to monetary reward stimuli. We further predict that the degree of normalization in fMRI activation will correlate with negative symptom improvement on aripiprazole. 